NYSE: STE · Medical Specialties

STERIS (STE) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values STERIS (STE) at $251.44 a share. The stock last closed at $261.91, which puts the model's fair value 4.0% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. STERIS plc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$251.44midpoint of 2,000 simulations
Last close$261.91NYSE: STE
Gap to fair value-4.0%fair value against price
Model verdictFairly valuedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $240.31 to $251.44 (+4.6%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.

What the model makes of itThe price of $261.91 is 4.0% above it: Fairly valued, on a medium evidence grade.

What's nextNext report on 3 Feb 2027. Options prices imply a move of about 7% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give STE?

The calibrated range for STE over 63 trading days is $241.71 to $284.95. It sits around the last close, and its width comes from the volatility that STE's own options imply (24% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $200.72 to $312.84. In 43% of the simulations the fair value came out above the price the model ran on.

$148.72$417.93
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $251.44. Dashed line: the last close, $261.91.

Faircurve Insights · 14 Nov 2026

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally.

Faircurve's model put the fair value at $251.44 a share on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $240.31, so the fair value moved +4.6%. In the model's own words, the stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $241.71 to $284.95, and ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium. The grade covers input completeness, peer count and agreement, and the spread of outcomes. It does not say whether the fair value is right.

STERIS scores 60 out of 100 on quality against comparable companies. Balance sheet is its strongest factor at 84, with Net debt / EBITDA of 0.99x against a peer median of 3.30x. Stability scores 79, with EBITDA margin downside volatility over 5y of 1.5 pts against a peer median of 9.2 pts. Profitability is weakest at 42, with ROIC of 9.8% against a peer median of 10.7%. The model compares it with United Therapeutics Corporation (UTHR), Incyte Corporation (INCY), Viatris Inc. (VTRS), Quest Diagnostics Incorporated (DGX), Roivant Sciences Ltd. (ROIV) and Tenet Healthcare Corporation (THC).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does STE report earnings, and how has the stock reacted?

STERIS's next earnings report is scheduled for 3 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 5.7% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. STE's 30 day implied volatility works out to about 7.0% over one month.

On 13 Nov 2026 STE moved 4.3% in one session, against the 1.6% a day that options had priced: 2.7 times the implied size.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across STE's last 8 reports, ignoring direction, was 6.2%.

0%5%10%no quote2.8%5 Feb '25no quote6.8%14 May '257.5%5.5%6 Aug '25no quote7.5%5 Nov '25no quote6.8%4 Feb '26no quote1.6%11 May '26no quote0.5%5 Aug '266.9%9.8%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in STE

0%5%10%15%4 Nov '26 report5 Aug '26 report11 May '26 report4 Feb '26 report7% at 16 Nov '2621 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 6% on 21 Nov 2025, reached 11% on 29 Oct 2026 and reads 7% on 16 Nov 2026. The marks are report dates.

How does STE score on business quality?

STERIS's overall quality score is 60 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.429.8%ROIC10.7%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).641.13xFCF / net income1.49x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.588.7%Revenue growth, trailing2.8%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.661.3%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.840.99xNet debt / EBITDA3.30x
StabilityDownside volatility of the EBITDA margin over the last five years.791.5 ptsEBITDA margin downside volatility, 5y9.2 pts

How does STE compare with similar companies?

The companies in medical specialties closest to STERIS in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
QDEL QuidelOrtho Corporation$10.21$15.28+49.7%Low evidence grade
UTHR United Therapeutics Corporation$587.88$601.98+2.4%Fairly valued
INSM Insmed Incorporated$122.88$113.05-8.0%Low evidence grade
INCY Incyte Corporation$120.27$136.90+13.8%Fairly valued
VTRS Viatris Inc.$20.74$26.77+29.1%Undervalued
DGX Quest Diagnostics Incorporated$262.21$314.32+19.9%Undervalued
ROIV Roivant Sciences Ltd.$38.61$26.96-30.2%Overvalued
THC Tenet Healthcare Corporation$291.54$371.67+27.5%Undervalued

What the comparable companies' multiples alone would give for STE, the peer-implied price, is $175.79 a share on this run. The fair value weighs that against the company's own multiple.

All healthcare stocks ranked by gap to fair value

STERIS at a glance

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences.

Market value
$25.7B
Sector
Healthcare
Industry
Medical Specialties
Revenue expected, next twelve months
$6.6B
Consensus revenue growth, next fiscal year
+7.4%
Analysts with estimates
5
Beta to the US market
0.30
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. STE was not among them.

How the fair value is worked out: the model prices STERIS on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for STE was $240.31. As of 14 Nov 2026 it is $251.44, a change of +4.6%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about STERIS's valuation

Is STERIS stock undervalued or overvalued?

On Faircurve's model, STE reads as Fairly valued as of 14 Nov 2026. The model's fair value is $251.44 a share against a last close of $261.91, a gap of -4.0%.

What is STE's fair value?

$251.44 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $200.72 to $312.84.

What price range does the model give STE?

$241.71 to $284.95 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does STERIS report earnings next?

The next report is scheduled for 3 Feb 2027. Companies can move their dates.

How much has STE moved on past earnings reports?

Across its last 8 reports the median two session move was 6.2%, ignoring direction. The largest was +9.8% around the report of 4 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for STE is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on STE

The model holds no idea open on STE today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on STE with their outcomes. A free account is enough.

Keep reading